Major histocompatibility complex (MHC) class I-related chain A gene (MICA) is a highly polymorphic gene located on the short arm of chromosome 6 (6p21.33), close to the HLA-B locus. MICA encodes a cell-stress-inducible glycoprotein (exons 2-4 of MICA for synthesis of three extracellular domains, and exon 5 for transmembrane domain), that mediates activation of NKG2D receptor expression on NK cells, CD8+ αβ and γδ T cells, and NK T cells [1, 2] . The MICA polymorphism (MICA-129 and MICA A5.1) has been shown to influence NKG2D signaling [3] and NKG2D polymorphisms are associated with natural cytotoxic activity (see Supplemental Data for details) [4] .
Allogenic hematopoietic stem cell transplantation (HSCT) is a well-established treatment for a variety of diseases affecting the immune and hematopoietic systems. Adverse post-HSCT clinical outcomes are still frequent, and notably include graft-versus-host disease (GVHD). Ensuring a high degree of donor-recipient HLA matching (i.e., 10 out of 10 matched HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 alleles) is one of the most important ways of decreasing the risk of post-HSCT complications. The role of MICA in this context has been examined, especially with regard to the impact of MICA-129 val/val on the incidence of chronic GVHD (cGVHD) [5] , and the correlation between MICA-129 mismatches and poor disease-free survival [6] . Moreover, in a cohort of 922 unrelated donorrecipient pairs matched for 10 out of 10 HLA alleles, MICA mismatches were associated with a significantly elevated incidence of grade III-IV acute GVHD (aGVHD), cGVHD, and relapse-free mortality (RFS). [7] The objective of the present study was to determine whether polymorphisms at the MICA and NKG2D loci are associated with adverse post-HSCT outcomes. Materials, methods and study population's demographic characteristics (Table S1 ) are presented in supplemental data. Briefly MICA and NKG2D genotyping were retrospectively performed on 124 pairs of recipients with hematological malignancies and their related or unrelated HLA-matched donors. Following conditioning, each recipient had undergone HSCT with a T-cell-replete graft from a related or unrelated HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1-matched donor. We did not include patients with alternative donors (haploidentical donor, donor with HLA mismatch), and transplantation with umbilical cord blood as stem cell sources. None of the recipients had undergone allogenic transplantation previously. We also excluded patients with benign diseases. With regard to the present study data, patients were monitored up until September 2017. Conditioning regimens were defined in table S1. Anti-T-cell treatments (such as anti-thymocyte globulin therapy) were used for only six patients. All patients received cyclosporine-based regimens for GVHD prophylaxis. The median (range) follow-up time was 22.4 months (0.2-58.4).
In our study population, each patient was ranked according to its highest grade of aGVHD during follow-up. 106 recipients (66.5%) experienced aGVHD. 28 of these (26%) had grade I disease, and 78 (74%) had grade II-IV disease (Table 1) .
MICA/NKG2D polymorphisms were analyzed in the study population of related and unrelated HLA-matched donor-recipient pairs. The observed overall frequencies (out of 159, in all cases) are summarized in supplemental data (text and table S2).
aGVHD occurred in 54 of the 70 MICA A5.1 heterozygotes (77%); this proportion was significantly higher than for MICA A5.1 homozygotes (15 out of 29, 52%) or for recipients lacking the mutation (37 out of 60, 62%; Fig. 1 ). In a competing risk analysis, heterozygosity for MICA A5.1 was associated with aGVHD regardless of the grade (p = 0.0130; hazard ratio = 2.49 (1.47; 3.46)) but not MICA A5.1 homozygosity (p = 0.6324; hazard ratio = 0.95 (0.44; 1.65)).
Furthermore 49 of the 74 recipients (66%) with the MICA-129 (val/val) polymorphism and 57 of the 85 recipients (67%) with MICA-129-met alleles developed aGVHD. This difference was not statistically significant.
About NKG2D polymorphisms, 60 of the 74 recipients (70%) with an NKC3 LNK1/LNK1 (C/C) donor, experienced aGVHD; compared with 46 of the 85 recipients (54%) with an HNK1 donor (HNK1/LNK1 or HNK1/ HNK1). 78 of the 103 recipients (76%) with an NKC4 LNK2/LNK2 (C/C) donor, experienced aGVHD; compared with 28 of the 56 recipients (50%) with an HNK2 donor (HNK2/LNK2 or HNK2/HNK2). Unfortunately, in a competing risk analysis, LNK1/LNK1 and LNK2/LNK2 donor haplotypes were not associated with aGVHD occurrence in recipient.
Moreover, 41 recipients developed cGVHD (Table 1) . We showed that 17 of the 70 MICA A5.1 heterozygotes (24%) developed cGVHD. The corresponding values were 4 out of 29 (13.8%) for homozygotes and 14 of 60 (23.3%) for recipients lacking this allele. This difference was not statistically significant.
Furthermore, MICA-129, NKC3 and NKC4 status were not correlated with the incidence of cGVHD. Similarly, MICA A5.1, MICA-129, NKC4 and NKC3 status had no impact on OS, and RFS (Results for MICA A5.1 are presented in the Table 1 ). Others parameters (such as donorrecipient mismatches for the MICA genotype, MICA-129 and MICA A5.1, ABO blood group incompatibility, CMV and EBV reactivation, gender mismatch as male recipient and female donor) were not correlated with the clinical data (data not shown).
In a population of related and unrelated HLA-matched HSCT recipients and donors, we observed an association between MICA A5.1 heterozygosity in the recipient and significantly elevated incidences of aGVHD regardless of the grade. Unfortunately, we failed to discriminate grade I Others tested parameters (MICA-129, NKC3 and NKC4 polymorphisms) were not associated with the occurrence of aGVHD. Recipient MICA polymorphisms (MICA-129 and MICA A5.1) and donor NKG2D (HNK1/LNK1 and HNK2/ LNK2) polymorphisms did not influence OS and RFS, given that our follow-up period was relatively short (median: 22.4 months; range: 0.2-58.4) and our hematologic diagnoses were variously. According to these results, MICA A5.1 linked to a low NK cytotoxic activity may be associated with an elevated incidence of aGVHD. It has previously been reported that low cytotoxic activity of NK cells (due to the interaction with MICA-129 val/val or soluble MICA) promotes the emergence of GVHD [5] . Whereas the presence of anti-MICA antibodies decreases the serum level of soluble MICA and reduces this post-HSCT complication [5] . It is not clear why GVHD may be related to low NK cell activity, although it has been suggested that alloreactive NK cells control GVHD by eliminating the recipient's immature dendritic cells and hosttype antigen-presenting cells [8] . Olson et al. demonstrated that activated donor NK cells can efficiently eliminate alloreactive donor T cells in a NKG2D-dependent manner, following the upregulation of NKG2D ligands on the alloreactive T-cell population [9] . The specific roles of MICA and NKG2D have yet to be established.
With regard to MICA, the wild-type (A4) allele encoding the full-length protein sorts to the basolateral membrane of epithelial cells in the intestine (i.e., a site where it may interact with intraepithelial T and NK lymphocytes); in contrast, MICA A5.1 allele encodes a truncated protein, aberrantly transported to the apical surface [10] . Moreover, MICA A5.1 allele is associated with presence of a soluble isoform of MICA derived by the proteolytic shedding of membrane-bound MICA. Although soluble MICA can still interact with NKG2D, subsequent endocytosis of the receptor-ligand complex compromises cytolytic activity [11] .
Moreover, the treatment of NK cells with exosomes containing MICA*008 molecules (correlated with MICA A5.1) triggered the downregulation of NKG2D at the cell surface and led to a relative reduction in NK cytotoxicity; these changes were independent of NKG2D ligand expression by the target cell [12] . In contrast, exposure of CD8+ T cells to MICA*008-containing exosomes did not significantly affect the cells' ability to specifically lyse targets.
In a study of a small cohort (38 pairs recipient/donor), it had been suggested that MICA*008 protects against GVHD [13] . Thus, MICA A5.1's opposing effects on NK cells and CD8+ T cells might explain the elevated incidence of aGVHD. Moreover, the lack of a significant effect of MICA A5.1 homozygosity in the present study could be due to the unsufficient size of the studied population or could be suggest that the opposing effect is moderate in this situation -perhaps due to a potential negative impact on the cytotoxic activity of CD8+ T cells.
With regard to NKG2D, in patients with hematological malignancies and standard-risk disease; it has previously been shown that the donor HNK1 haplotype is associated with significantly longer OS and a lower TRM rate but was not associated with disease relapse or development of aGVHD or cGVHD. In contrast, these results were not found in patients with high-risk disease [14] . Moreover, expression of the activating NKG2C receptor (another member of the NKG2 family) is significantly lower in NK cells after HSCT in patients with severe GVHD [15] . We can therefore hypothesize that donor NK cells, with a low level of cytotoxic activity against host-type antigen-presenting cells, might promote GVHD via CD8+ cells [16] .
In conclusion, our present results show that recipient MICA A5.1 heterozygosity was associated with aGVHD after HSCT. Others studied MICA and NKG2D polymorphisms failed to show a link with clinical outcome, probably due to the size of our studied population. However, recipient MICA polymorphisms may be useful transplantation markers-notably in fully HLA-matched HSCT. Our results further suggest that pretransplantation screening should encompass MICA polymorphisms in the recipient. However, a definitive assessment of the feasibility of this approach would require a prospective, randomized study.
